

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Adherium Limited
ABN 24 605 352 510

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	George Baran
Date of last notice	8 January 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Trudell Medical Limited - Mr Baran has a 33.33% beneficial interest in Trudell Medical Limited
Date of change	24 February 2026

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>Direct</p> <ul style="list-style-type: none"> - 7,500,000 Fully paid ordinary shares <p>Indirect</p> <ul style="list-style-type: none"> - 842,002,695 Fully paid ordinary shares - 699,064 Options over fully paid ordinary shares, exercisable at \$0.3285 each and expiring on 29 January 2027 - Nil Convertible Notes - 165,696,427 Unlisted Options exercisable at 2 cents expiring on 28 February 2028 - 85,000,000 Unlisted Options exercisable at half a cent, expiring on 15 November 2026
Class	Fully Paid Ordinary Shares
Number acquired	<p>Indirect</p> <ul style="list-style-type: none"> - 561,335,130 Fully Paid Ordinary Shares
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.003 (0.3 cents) per share
No. of securities held after change	<p>Direct</p> <ul style="list-style-type: none"> - 7,500,000 Fully Paid Ordinary Shares <p>Indirect</p> <ul style="list-style-type: none"> - 1,403,337,825 Fully Paid Ordinary Shares - 699,064 Options over fully paid ordinary shares, exercisable at \$0.3285 each and expiring on 29 January 2027 - Nil Convertible Notes - 165,696,427 Unlisted Options exercisable at 2 cents expiring on 28 February 2028 - 85,000,000 Unlisted Options exercisable at half a cent, expiring on 15 November 2026
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-backex</small>	Issue of Fully Paid Ordinary Shares under the ANREO (Institutional Offer).

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.